Today: 30 June 2026
Rocket Lab stock whipsaws on Neutron tank rupture; what RKLB investors watch next
23 January 2026
1 min read

Rocket Lab stock whipsaws on Neutron tank rupture; what RKLB investors watch next

New York, Jan 22, 2026, 17:36 EST — After-hours

  • Rocket Lab shares ended flat following an early drop linked to a Neutron test failure
  • Company said it is reviewing data to assess any impact on the Neutron launch timeline
  • Rocket Lab announced a successful Electron launch for newcomer Open Cosmos

Shares of Rocket Lab Corporation closed Thursday up 0.2%, finishing at $87.98. The stock saw a wide range, swinging between $81.35 and $89.40, as investors digested a test failure on the company’s next-gen Neutron rocket alongside new details about an Electron launch.

This move is crucial as Neutron represents Rocket Lab’s push beyond just small-satellite launches into heftier missions. The stakes rise sharply here, with bigger payoffs but tighter deadlines that don’t tolerate delays.

Any delay would force Rocket Lab to rely even more heavily on its smaller Electron rocket and space-systems business, while competitors with bigger rockets maintain their edge in bulk launch capacity.

Rocket Lab revealed in a Wednesday filing that a Neutron Stage 1 tank ruptured during a hydrostatic pressure test—where liquid is used to verify structural integrity under load. The company reported no major damage to either the test rig or facilities. Another Stage 1 tank is already being built as Rocket Lab reviews the data to assess any impact on the launch timeline.

Rocket Lab described the incident as routine qualification testing, noting it “intentionally” pushes structures to their limits to confirm safety margins ahead of flights. The company, however, didn’t specify whether this would affect the schedule.

Just hours later, the company highlighted strong operational momentum with its current launcher, completing its first Electron mission of 2026. It successfully deployed two satellites into a 1,050 km circular orbit for Open Cosmos. Founder and CEO Sir Peter Beck described the launch as “a great showcase” for Electron’s dedicated missions. GlobeNewswire

TD Cowen analyst Gautam Khanna flagged that the tank problem might disrupt Rocket Lab’s 2026 schedule if it causes a delay. “If a launch delay results from the tank rupture, a second Neutron launch in 2026 would be unlikely,” he noted in a Jan. 21 report. Aviation Week

Neutron sits at the heart of Rocket Lab’s strategy to handle bigger payloads and ramp up launch frequency, a space where SpaceX currently leads and clients expect firm scheduling.

Bulls face the risk that the review uncovers a design or manufacturing issue requiring more time than investors anticipate, delaying key milestones and driving up the cost to reach first flight.

Investors are eyeing Rocket Lab’s fourth-quarter earnings call in February, where the company plans to provide an update on the Neutron timeline. The exact date for the earnings release hasn’t been set, but MarketBeat currently projects it around Feb. 26.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Autodesk layoffs: AutoCAD maker to cut 1,000 jobs as it shifts spending to AI and cloud
Previous Story

Autodesk layoffs: AutoCAD maker to cut 1,000 jobs as it shifts spending to AI and cloud

British American Tobacco share price in focus before London open after buyback disclosure
Next Story

British American Tobacco share price in focus before London open after buyback disclosure

Go toTop